Abstract:Abstract Rare neurological diseases, while Individually are rare, collectively Impact millions globally, leading to diverse and often severe neurological symptoms. Often attributed to genetic mutations that disrupt protein function or structure, understanding their genetic basis is crucial for accurate diagnosis and targeted therapies. To investigate the underlying pathogenesis of these conditions, researchers often use non-mammalian model organisms, such as Drosophila (fruit flies), which is valued for their genetic manipulability, cost-efficiency, and preservation of genes and biological functions across evolutionary time. Genetic tools available in Drosophila, including CRISPR-Cas9, offer a means to manipulate gene expression, allowing for a deep exploration of the genetic underpinnings of rare neurological diseases. Drosophila boasts a versatile genetic toolkit, rapid generation turnover, and ease of large-scale experimentation, making it an invaluable resource for identifying potential drug candidates. Researchers can expose flies carrying disease-associated mutations to various compounds, rapidly pinpointing promising therapeutic agents for further investigation in mammalian models and, ultimately, clinical trials. In this comprehensive review, we explore rare neurological diseases where fly research has significantly contributed to our understanding of their genetic basis, pathophysiology, and potential therapeutic implications. We discuss rare diseases associated with both neuron-expressed and glial-expressed genes. Specific cases include mutations in CDK19 resulting in epilepsy and developmental delay, mutations in TIAM1 leading to a neurodevelopmental disorder with seizures and language delay, and mutations in IRF2BPL causing seizures, a neurodevelopmental disorder with regression, loss of speech, and abnormal movements. And we explore mutations in EMC1 related to cerebellar atrophy, visual impairment, psychomotor retardation, and gain-of-function mutations in ACOX1 causing Mitchell syndrome. Loss-of-function mutations in ACOX1 result in ACOX1 deficiency, characterized by very-long-chain fatty acid accumulation and glial degeneration. Notably, this review highlights how modeling these diseases in Drosophila has provided valuable insights into their pathophysiology, offering a platform for the rapid identification of potential therapeutic interventions. Rare neurological diseases involve a wide range of expression systems, and sometimes common phenotypes can be found among different genes that cause abnormalities in neurons or glia. Furthermore, mutations within the same gene may result in varying functional outcomes, such as complete loss of function, partial loss of function, or gain-of-function mutations. The phenotypes observed in patients can differ significantly, underscoring the complexity of these conditions. In conclusion, Drosophila represents an indispensable and cost-effective tool for investigating rare neurological diseases. By facilitating the modeling of these conditions, Drosophila contributes to a deeper understanding of their genetic basis, pathophysiology, and potential therapies. This approach accelerates the discovery of promising drug candidates, ultimately benefiting patients affected by these complex and understudied diseases.

Knockdown of the GABARAP ortholog Atg8a elicits deficits in learning and promotes obsessive behaviors in Drosophila melanogaster

Neurofibromin Loss of Function Drives Excessive Grooming in Drosophila

Targeting of retrovirus-derived Rtl8a/8b reduces social response and increases apathy-like behavior associated with GABRB2 reduction

Drosophila models of PIGA-CDG mirror patient phenotypes

Drosophila mutants lacking octopamine exhibit impairment in aversive olfactory associative learning

Metabolic and neurobehavioral disturbances induced by purine recycling deficiency in Drosophila

Functional Analysis of Human GBA1 Missense Mutations in Drosophila: Insights into Gaucher Disease Pathogenesis and Phenotypic Consequences

Potent New Targets for Autophagy Enhancement to Delay Neuronal Ageing

Drosophila models of phosphatidylinositol glycan biosynthesis class A congenital disorder of glycosylation (PIGA-CDG) mirror patient phenotypes

Insights into Dentatorubral-Pallidoluysian Atrophy from a new Drosophila model of disease

Autophagic dysfunction and gut microbiota dysbiosis cause chronic immune activation in a Drosophila model of Gaucher disease

Impairment of the glial phagolysosomal system drives prion-like propagation in a Drosophila model of Huntington's disease

Modeling neurodegenerative and neurodevelopmental disorders in the Drosophila mushroom body

Modulating glial genes involved in synaptic function mitigates pathogenesis and behavioral deficits in a<i>Drosophila</i>model of Huntington’s Disease

Rats Lacking the Dopamine Transporter Display Inflexibility in Innate and Learned Behavior

Altered habituation of an identified escape circuit in Drosophila memory mutants

Associative Learning Requires Neurofibromin to Modulate GABAergic Inputs to Drosophila Mushroom Bodies

Altered Grooming Cycles in Transgenic Drosophila

Exploiting fly models to investigate rare human neurological disorders

OCD-Like behaviors caused by a neuropotentiating transgene targeted to cortical and limbic D1+ neurons

Electroconvulsive seizure behavior in Drosophila: analysis of the physiological repertoire underlying a stereotyped action pattern in bang-sensitive mutants